Tabata Tsutomu
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine
   Position   Professor and Division head
Article types Original article
Language English
Peer review Peer reviewed
Title The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG.
Journal Formal name:Journal of gynecologic oncology
Abbreviation:J Gynecol Oncol
ISSN code:20050399/20050380
Domestic / ForeginForegin
Volume, Issue, Page 31(6),pp.e94
Author and coauthor Kondo Eiji, Tabata Tsutomu, Suzuki Nao, Aoki Daisuke, Yahata Hideaki, Kotera Yoshio, Tokuyama Osamu, Fujiwara Keiichi, Kimura Eizo, Terauchi Fumitoshi, Sumi Toshiyuki, Okamoto Aikou, Yaegashi Nobuo, Enomoto Takayuki, Sugiyama Toru
Authorship 2nd author
Publication date 2020/11
Summary OBJECTIVE:In this study we sought to investigate the clinical factors that affect post-progression survival (PPS) in patients with recurrent or persistent clear cell carcinoma (CCC). We utilized the JGOG3017/Gynecological Cancer InterGroup data to compare paclitaxel plus carboplatin (TC) and irinotecan plus cisplatin (CPT-P) in the treatment of stages I to IV CCC.METHODS:We enrolled 166 patients with recurrent or persistent CCC and assessed the impact of variables, including platinum sensitivity, treatment arm, crossover chemotherapy, primary stage, residual tumor at primary surgery, performance status, ethnicity, and tumor reduction surgery at recurrence on the median of PPS in patients with recurrent or persistent CCC.RESULTS:A total of 77 patients received TC, and 89 patients received CPT-P. The median PPS for patients with platinum-resistant disease was 10.9 months, compared with 18.8 months for patients with platinum-sensitive disease (hazard ratio [HR]=1.88; 95% confidence interval [CI]=1.30-2.72; log-rank p<0.001). In the multivariate analysis, the platinum sensitivity (resistant vs. sensitivity; HR=1.60; p=0.027) and primary stage (p=0.009) were identified as independent predictors of prognosis factors for PPS in recurrent or persistent CCC.CONCLUSIONS:Our findings revealed that platinum sensitivity and primary stage are clinical factors that significantly affect PPS in patients with recurrent or persistent CCC as well as other histologic subtypes of ovarian cancer. PPS in patients with recurrent CCC should establish the basis for future clinical trials in this population.
DOI 10.3802/jgo.2020.31.e94
PMID 33078599